Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Delivery
- Therapeutic
- Pharmaceuticals
- Disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 93552
License Grant
The signing a joint venture license agreement for three programs utilizing Licensor’s LTP (Liver Targeting Prodrug) technology with Licensee, a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China.
License Property
Licensor’s LTP technology is a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver. By directly targeting the liver, the goal is to maximize efficacy and minimize off-target drug toxicities.
The preclinical programs under this license include NUC-202, a targeted anti-cancer analog for the treatment of hepatocellular carcinoma; NUC-404, a targeted nucleotide analog for the treatment of hepatitis B; and NUC-101, a targeted nucleotide analog for the treatment of hepatitis C.
LTP is a promising technology platform developed by Licensor with applicability in a range of hepatic and hepatic-mediated indications. Given the increased focus on liver-related health by drug companies and the substantial medical need in China for liver-related medicines
Field of Use
This agreement pertains to the drug industry relating to liver-related treatments.
IPSCIO Record ID: 10115
License Grant
The Canadian Company said that it agreed to purchase worldwide patents and intellectual property related to drug delivery technology. The agreement allows the Company to pursue the development of this technology, either by itself or in partnerships.
License Property
The principles behind hemoglobin drug delivery are similar to those that form the basis for the current therapeutic monoclonal antibody products currently used in the treatment and diagnosis of certain cancers.
This technology effectively links anti-viral and anti-cancer drugs to purified hemoglobin, the starting material for Hemolink. The created hemoglobin-drug complex is then transported to the liver through the natural pathway for hemoglobin uptake and clearance from the blood plasma. This could allow for targeted delivery of anti-viral drugs to the liver in the case of patients suffering from Hepatitis C, and anti-cancer drugs in the case of patients with cancers of the liver. It is expected that at least two drug delivery compounds will move into preclinical development.
IPSCIO Record ID: 385607
License Grant
This amendment modifies royalties and clarifies Anti-corruption compliance.
License Property
The original agreement is for Fablyn (lasofoxifene tartrate), a selective estrogen receptor modulator (SERM) intended for the treatment of osteoporosis in postmenopausal women.
Pradefovir is a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Field of Use
HepDirect technology license is for the discovery, development and commercialization of new compounds in hepatitis B (HepB), hepatitis C (HepC) and hepatocellular carcinoma (HCC).
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.
IPSCIO Record ID: 383572
License Grant
Licensor grants an exclusive, even as to Licensor, worldwide, right and license, with the right to sublicense, and to further sublicense, under the Licensor Technology to research, Develop, manufacture, have manufactured, use, import and Commercialize the Licensed Products in and for the Field.
License Property
Licensor has developed Liver Targeting Prodrug Technology prodrugs comprising of the Compounds.
Compound means an Agents prodrug that utilizes the Licensor Liver Targeting Prodrug Technology and is discovered or Developed by or for the account of a Party pursuant to such Partys performance of its obligations under this Agreement.
Agent means any of the following natural omega-3 fatty acids
— EPA (i.e., icosapentaenoic acid) or an EPA ester,
— DHA (i.e., docosahexaenoic acid) or a DHA ester,
— a combination of EPA (or an EPA ester) with DHA (or a DHA ester) or,
— any of the individual omega-3 fatty acids or a complex mixture of the omega-3 fatty acids contained (as of the Effective Date) within EpanovaTM.
Licensor Liver Targeting Prodrug Technology means Licensors program for the development of a liver-specific drug targeting technology for chemically modifying the molecule to render it inactive until the modification is cleaved off by a liver-specific enzyme, including all related intellectual property and other related rights of Licensor, and any and all related clinical and non-clinical data compiled by Licensor, in each case arising from the Licensors operation of such program.
The patents include
Prodrug compounds and uses for Liver Targeting;
Prodrug compounds and uses thereof; and,
Prodrug compounds and their uses thereof.
Field of Use
The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP TECHNOLOGYâ„¢ to improve lipid-lowering activity of certain omega-3 fatty acids. LTP TECHNOLOGY is a broadened novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver. It works by chemically modifying a biologically active molecule into an inactive prodrug form that will be administered and later activated in the liver by certain enzymes mainly expressed in the liver. The technology can be used to improve activity and/or safety of an existing drug or to develop new agents to treat liver diseases or diseases caused by homeostasis imbalance of circulating biomolecules controlled by the liver such as lipids and glucose, and is especially applicable to metabolic and cardiovascular diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
